# An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome

> **NCT05832255** · PHASE2 · SUSPENDED · sponsor: **Nova Mentis Life Science Corp** · enrollment: 10 (estimated)

## Conditions studied

- Fragile X Syndrome
- Behavior
- Cognitive Dysfunction

## Interventions

- **DRUG:** Psilocybin, 1.5 mg

## Key facts

- **NCT ID:** NCT05832255
- **Lead sponsor:** Nova Mentis Life Science Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-03-28
- **Primary completion:** 2024-05
- **Final completion:** 2024-05
- **Target enrollment:** 10 (ESTIMATED)
- **Why stopped:** Indefinite hold due to protocol revisions relating to the exclusion criteria for concurrent medications.
- **Last updated:** 2024-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05832255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05832255, "An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05832255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*